Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea.
J Clin Oncol. 2020 Oct 1;38(28):3304-3313. doi: 10.1200/JCO.20.01210. Epub 2020 Aug 20.
It is unclear whether laparoscopic distal gastrectomy for locally advanced gastric cancer is oncologically equivalent to open distal gastrectomy. The noninferiority of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer compared with open surgery in terms of 3-year relapse-free survival rate was evaluated.
A phase III, open-label, randomized controlled trial was conducted for patients with histologically proven locally advanced gastric adenocarcinoma suitable for distal subtotal gastrectomy. The primary end point was the 3-year relapse-free survival rate; the upper limit of the hazard ratio (HR) for noninferiority was 1.43 between the laparoscopic and open distal gastrectomy groups.
From November 2011 to April 2015, 1,050 patients were randomly assigned to laparoscopy (n = 524) or open surgery (n = 526). After exclusions, 492 patients underwent laparoscopic surgery and 482 underwent open surgery and were included in the analysis. The laparoscopy group, compared with the open surgery group, suffered fewer early complications (15.7% 23.4%, respectively; = .0027) and late complications (4.7% 9.5%, respectively; = .0038), particularly intestinal obstruction (2.0% 4.4%, respectively; = .0447). The 3-year relapse-free survival rate was 80.3% (95% CI, 76.0% to 85.0%) for the laparoscopy group and 81.3% (95% CI, 77.0% to 85.0%; log-rank = .726) for the open group. Cox regression analysis after stratification by the surgeon revealed an HR of 1.035 (95% CI, 0.762 to 1.406; log-rank = .827; for noninferiority = .039). When stratified by pathologic stage, the HR was 1.020 (95% CI, 0.751 to 1.385; log-rank = .900; for noninferiority = .030).
Laparoscopic distal gastrectomy with D2 lymphadenectomy was comparable to open surgery in terms of relapse-free survival for patients with locally advanced gastric cancer. Laparoscopic distal gastrectomy with D2 lymphadenectomy could be a potential standard treatment option for locally advanced gastric cancer.
腹腔镜下局部进展期胃癌远端胃切除术的肿瘤学疗效是否与开腹手术相当仍不明确。本研究旨在评估腹腔镜下局部进展期胃癌根治性全胃切除术与开腹手术相比在 3 年无复发生存率方面的非劣效性。
进行了一项 III 期、开放性、随机对照试验,纳入了适合行远端胃大部切除术的局部进展期胃腺癌组织学证实患者。主要终点为 3 年无复发生存率;腹腔镜组和开腹组的非劣效性上限 HR 为 1.43。
2011 年 11 月至 2015 年 4 月,共随机分配 1050 例患者接受腹腔镜(n = 524)或开腹手术(n = 526)。排除后,492 例患者接受腹腔镜手术,482 例患者接受开腹手术并纳入分析。与开腹组相比,腹腔镜组的早期并发症(15.7%比 23.4%; =.0027)和晚期并发症(4.7%比 9.5%; =.0038)发生率较低,特别是肠梗阻(2.0%比 4.4%; =.0447)。腹腔镜组和开腹组的 3 年无复发生存率分别为 80.3%(95%CI,76.0%85.0%)和 81.3%(95%CI,77.0%85.0%;对数秩检验 =.726)。分层后的 Cox 回归分析显示,手术医生分层后的 HR 为 1.035(95%CI,0.7621.406;对数秩检验 =.827;非劣效性检验 =.039)。分层后的病理分期 HR 为 1.020(95%CI,0.7511.385;对数秩检验 =.900;非劣效性检验 =.030)。
对于局部进展期胃癌患者,腹腔镜下局部进展期胃癌根治性全胃切除术与开腹手术相比,无复发生存率相当。腹腔镜下局部进展期胃癌根治性全胃切除术可能是局部进展期胃癌的一种潜在标准治疗选择。